The aim of the present study was to test the hypothesis that sandblasted and acid etched titanium surfaces can be functionalised with vascular endothelial growth factor (VEGF) using oligonucleotides for anchorage and slow release. rhVEGF165 molecules were conjugated to strands of 30-mer non-coding DNA oligonucleotides (ODN) and hybridised to complementary ODN anchor strands which had been immobilised to the surface of sandblasted/acid etched (SAE) Ti specimens. Specimens with non-conjugated VEGF adsorbed to ODN anchor strands and to blank SAE surfaces served as controls. Specifi c binding of conjugated VEGF exhibited the highest percentage of immobilised VEGF (71.0 %), whereas non-conjugated VEGF only achieved 53.2 and 30.7 %, respectively. Cumulative release reached 54.0 % of the immobilised growth factor in the group of specifi cally bound VEGF after 4 weeks, whereas non-conjugated VEGF adsorbed to ODN strands released 78.9 % and VEGF adsorbed to SAE Ti surfaces released 97.4 %. Proliferation of human umbilical vein endothelial cells (HUVECs) was signifi cantly increased on the surfaces with specifi cally bound VEGF compared to the control surfaces and SAE Ti surfaces without VEGF. Moreover, the released conjugated VEGF exhibited biological activity by induction of von Willebrand Factor (vWF) in mesenchymal stem cells. It is concluded that the angiogenic functionalisation of SAE titanium surfaces can be achieved by conjugation of VEGF to ODN strands and hybridisation to complementary ODN strands that are anchored to the titanium surface. The angiogenic effect is exerted both through the immobilised and the released portion of the growth factor.
Introduction
Periimplant bone formation constitutes the basis for the successful integration of endosseous titanium implants by establishing an intimate contact between bone tissue and the implant surface. This process is osteoconductive in nature and requires angiogenesis not only to provide blood supply for tissue formation but also to bring perivascular osteoprogenitor cells to the site of osteogenesis (Park and Davies, 2000) . Excessive trauma, radiation therapy or systemic diseases can reduce the angiogenic capacity of periimplant bone tissue and thereby compromise the process of osseointegration (Nociti et al. 2002; Keller et al. 2004; Javed and Romanos, 2009; Javed et al., 2010) . In these cases, a bioactive implant surface that improves the process of bone formation through enhancement of angiogenesis would be of considerable clinical benefi t.
The biological performance of implant surfaces has been improved through increased surface roughness, which facilitates the adsorption of serum proteins and other biomolecules as well as the attachment of platelets (Park and Davies, 2000; Boukari et al., 2006) . The increased release of growth factors due to surface microstructure and energy from cells growing on the surface (Raines et al., 2010) as well as subsequently enhanced platelet attachment to the implant surface has shown to enhance the process of tissue formation and of angiogenesis (Davies et al., 2003) . A more direct approach to the improvement of bone formation through the enhancement of angiogenesis is the use of angiogenic growth factors (Kleinheinz et al., 2005; Kaigler et al., 2006; Poh et al., 2010; Wernike et al., 2010) . Some authors have explored the potential of collagen coatings with and without heparin on titanium surfaces in order to bind and release vascular endothelial growth factor (VEGF) (Wolf-Brandstetter et al., 2006; Mueller et al. 2011) . Others have used polysaccharides, polydopamine fi lms or copolymeric hydrogel coating in conjunction with VEGF to enhance the biologic quality of titanium implant surfaces (De Giglio et al., 2010; Hu et al., 2010; Poh et al., 2010) .
A critical aspect in bio-activation of implant surfaces is the mode of binding and release of angiogenic growth factors from the implant surface. Recent experimental results reporting on the use of VEGF to enhance angiogenesis suggest that a short-term release of higher amounts of VEGF after simple adsorption can impede formation of new vessels whereas a slow sustained release has been able to promote vascularisation (Wernike et al., 2010) . Other reports describe enhanced vessel formation with VEGF release at early periods (Leach et al., 2006) . However, a problem with growth factors integrated into H Schliephake et al. Angiogenesis on titanium surfaces a bioactive implant coating commonly arises when these implants undergo sterilisation in a commercial production process, because both gamma radiation and autoclaving can destroy the biological activity of the incorporated growth factors. Thus, a release system that allows for controlled binding and release of growth factors after sterilisation would be desirable to overcome this problem. Recently, a system of oligonucleotides nano-anchored to titanium surfaces through anodic polarisation has been developed which allows for specific binding of complementary oligonucleotides conjugated to bioactive molecules (Michael et al., 2007) . Moreover, it has been previously shown by our group that bone morphogenic proteins (BMP2) can be immobilised on the surface of sandblasted acid etched titanium with subsequent release as active molecule (Schliephake et al., 2012) . As the structure of oligonucleotides is likely to remain unaltered under certain conditions of γ-radiation (Reichert et al., 2011) they could be used as a system for release of peptide growth factors that are specifi cally bound to the oligonucleotides subsequent to gamma ray sterilisation immediately prior to insertion in the operation room. The aim of the present in vitro study was, thus, to test the hypothesis that oligonucleotides can be used for anchorage and slow release of angiogenic growth factors such as VEGF from a titanium surface to enhance its angiogenic activity.
Materials and Methods

Specimen fabrication
Commercially pure titanium discs of 14.7 mm diameter were prepared by sandblasting and subsequent acidetching (KLS Martin, Tuttlingen, Germany) (Fig. 1a,b) . The samples were etched in 5.1 M hydrochloric acid and 4.6 M sulphuric acid solution for 300 s by 108 °C (Scharnweber et al., 2010) . The 60-mer anchor strands were synthesised by Thermo Fisher Scientific (Ulm, Germany). The 31-mer Oligonucleotides (GS-ODN) to anchor strands were synthesised by Biomers (Ulm, Germany). For complementary immobilisation of anchor strands (AS) an electrochemical setup was used, which has already been described by Beutner et al. (2009) . Briefl y, the samples were mounted to the bottom of a conical cell made from polyetherimide. A conventional three-electrode setup was used with a spiral gold wire acting as auxiliary electrode and a saturated Ag/AgCl reference electrode connected to the cell via a salt bridge made from a tube fi lled with agarose gel (2 % w/v in 2 mol/L acetate buffer, pH 4.0). Initial adsorption inside the electrochemical cell was carried out in 300 μL of 0.5 mol/L acetate buffer at pH 4.0 with additional 5 mol/L ethanol for 15 min. The electrolyte contained 800 nmol/L AS. After adsorption time 6 mL buffer (with ethanol analogous to the adsorption electrolyte) were added to the cell and the anodic Angiogenesis on titanium surfaces polarisation was started within 20 s. The potentiostat/ galvanostat (Voltalab 4.0, Radiometer Analytical, Lyon, France) was operated in galvanostatic mode with 11 mA/ cm 2 to ensure a polarisation time of approx. 3 s to reach a potential of 7.5 V Ag/AgCl . Subsequently the cell was rinsed two times with 9 mL buffer, followed by dipping the samples in sterile deionised (SDI) H 2 O (0.055 mS/cm) to remove the buffer. After that treatment the samples were dried for 2 h at room temperature in the dark and fi nally packed in aluminium peel bags (Früh Verpackungstechnik, Fehraltorf, Switzerland) . The surface structure of the sandblasted acid etched (SAE) titanium surface with ODN strands is shown in Figs. 1c,d .
Conjugation of growth factors with complementary oligonucleotides (GS) was done by using disuccinimidyl suberate (DSS) as linker molecule. In a fi rst step the aminomodifi ed GS-ODN was activated with DSS in 1 mM acetate buffer pH 4.0. The excess DSS was separated using an Illustra NAP-10 column (GE Healthcare, Freiburg, Germany). The DSS-activated GS-ODN was mixed with rhVEGF165 (Reliatech, Braunschweig, Germany) in phosphate buffered saline (PBS) containing 2 M sodium chloride pH 7.4 and incubated at room temperature for at least 1 h.
Hybridisation of anchored oligonucleotides with growth factor conjugated with complementary oligonucleotides (VEGF-ODN)
For each disc, 100 μL of VEGF-ODN solutions were prepared as follows: 10 μL PBS, 80 μL pure water and 10 μL conjugated growth factor solution containing 1,800 ng of rhVEGF165 (Reliatech. Wolfenbüttel, Germany).
The volumes of 100 μL were pipetted onto the discs and left for hybridisation in a dark chamber at room temperature for 1 h. Care was taken to accommodate the complete volume on the disc surface. Subsequently, the specimens were washed four times in PBS. The amount of VEGF that was washed away was measured using a custom made commercially produced sandwich ELISA (Reliatech) according to the recommendation of the manufacturer.
Experimental design
The experiments comprised three series: 1. Evaluation of release of rhVEGF165 from the loaded titanium surfaces, 2. Specifi c activity related to growth factor loading and release was assessed using human umbilical vein endothelial cells (HUVECs), 3. Angiogenic activity of the released growth factor was measured through the induction of endothelial phenotype in human mesenchymal stem cells.
Release of growth factor rhVEGF165
For release experiments, Titanium discs with three different conditions were analysed in order to compare unspecifi c binding by adsorptive coating with specifi c binding through oligonucleotides:
• Group R1: Sandblasted acid-etched (SAE) (Fig.  1c,d ) surface with nano-anchored oligonucleotides (ODN) that were hybridised with complementary oligonucleotides conjugated to rhVEGF165 as described above. Assessment of washed-out VEGF indicated that 1,277.6 ng (71.0 %) of VEGF remained attached to the disc surface. • Group R2: SAE surface with nano-anchored oligonucleotides (ODN) and adsorbed non-conjugated rhVEGF165 to test for the effect of non-specifi c binding of VEGF to the ODN strands. Discs were loaded in an identical manner as described for Group R1. This yielded an adsorbed amount of 957 ng (53.2 %) of VEGF on the disc surface.
• Group R3: Blank SAE (Fig. 1a,b) surface without nano-anchored ODN and adsorbed non-conjugated rhVEGF165. Discs were loaded with VEGF by dripping 1,800 ng of VEGF in 100 μL onto the disc surface. The growth factors were allowed to adsorb for 1 h in a dark chamber at room temperature after which the discs were rinsed four times in PBS, leaving 553.3 ng (30.7 %) of VEGF attached to the disc surface.
The discs scheduled for the release experiments were placed in cell culture medium (DMEM, 1 g Glucose; Biochrom, Berlin, Germany) in bovine serum albumin (BSA) (Carl Roth, Karlsruhe, Germany) coated 24 well plates. The medium was collected and replaced after 24 h, 3 days and every 3-4 days thereafter until day 28. The amount of VEGF was assessed using the custom made commercially produced sandwich ELISA mentioned above. The minimum detectable amount was 100 pg/mL rhVEGF165. Three discs of each condition were evaluated and all measurements were performed in triplicate. The residual volume of the eluates was used for the induction experiments in mesenchymal stem cells.
Specifi c activity of the loaded Titanium surface
For the evaluation of the angiogenic activity of the loaded surface by assessment of HUVEC proliferation, the following groups were used:
• Group C1: Blank SAE surface.
• Group C2: SAE surface with adsorbed non-conjugated rhVEGF165. seeded onto each titanium disc and fresh cell culture medium without VEGF was added. The ability to induce HUVEC cell proliferation was expressed as an increase in cell numbers compared to the blank controls. Cell numbers were assessed using automated cell counting (CASY ® , Model TT; Roche Diagnostics, Mannheim, Germany) after 1, 3, 7 days and 4 weeks (Tillner et al., 1994) . Three discs of each condition were evaluated at each interval and all measurements were performed in triplicate.
Activity of the released rhVEGF165
Human mesenchymal stem cells (hMSCs, http://www. lonza.com) were expanded according to the instructions of the provider in mesenchymal stem cell growth medium provided by the manufacturer in order to assess the angiogenic activity ability of the released VEGF by induction of von Willebrand factor (vWF) as an indication for induction of an endothelial phenotype in hMSCs . Cells from passage 2 of the expanded hMSCs were used for the analysis. The cells were exposed to the media containing VEGF released from the discs on days 1, 3, 7 and 28. After 6 days the expression of vWF was assessed using immunocytochemistry. The cells were fi xed with 4 % paraformaldehyde (PFA, Carl Roth, for 7 min and permeabilised for 10 min. using Triton X-100 (0.1 %) (Sigma-Aldrich Chemie, Taufkirchen, Germany). For staining of the vWF, the primary antibody (ab6994, Abcam, www.abcam.com) (1:100) was added for 24 h with the secondary antibody Alexa Fluor (Invitrogen; www. invitrogen.com) (1:100) for 1 h. Phalloidin (1:100; 1 h) (Millipore, Merck Bioscience, Schwalbach, Germany) was employed to stain actin fi laments and nuclei were stained with DAPI (1:1000; 20 min) (Millipore). Inductions were performed in duplicate.
Statistics
Repeated measures ANOVA (PASW Statistics 18.0, http:// support.spss.com) were used to compare the release kinetics between the three different surfaces. Univariate ANOVA with Bonferroni correction was employed to compare proliferation of HUVECs. All tests were performed at a signifi cance level of p < 0.05.
Results
Release of rhVEGF165 SAE surfaces that had been loaded with non-conjugated VEGF showed a burst release with a range of 90 ng/mL to 41 ng/mL within the fi rst three days with a rapid decline in release until day 7. The release of non-conjugated VEGF from the surfaces equipped with ODN strands was even higher with 138.9 ng/mL and 101.8 ng/mL during the fi rst two intervals. The release from surfaces loaded with conjugated VEGF hybridised to nano-anchored oligonucleotides exhibited a burst release kinetic, too with a high release during the fi rst 5 days between 87.1 ng/mL and 104.9 ng/mL. The release after the fi rst week showed that the surface loaded with conjugated VEGF hybridised to nano-anchored oligonucleotides had a signifi cantly higher release from day 10 to the end of the observation period than the surface loaded with non-conjugated VEGF (Fig.  2a) . Differences in release between the three groups were signifi cant only at day 14 and at day 28 (p < 0.001 and p = 0.008, respectively).
Calculation of the cumulative release showed that the rapid desorption of non-conjugated rhVEGF165 from the SAE surfaces has led to an almost complete release after one week (95.3 %, SD: 0.2) which did hardly change until the end of the observation period (97.4 %, SD: 0.01) The release of non-conjugated rhVEGF165 from ODN equipped SAE surfaces was identical in the fi rst three days where after it slowed down reaching a plateau at 77.6 % (SD: 0.07) after one week, too, with almost no change until day 28 (78.9 %, SD: 0.01). The SAE surface with ODN strands and conjugated rhVEGF165 exhibited the slowest increase with a plateau also after one week, however only at 52.8 % (SD: 0.03). After that no changes in percentage of release occurred over the following three weeks (54.0 %, SD 0.01) (Fig. 2b) .
Proliferation of HUVECs
During the 4 weeks of culture HUVECs proliferated from 30,000 cells to 69,895 and 93,432 cells on average, respectively, both on the uncoated SAE surface as well as on the surface loaded with non-conjugated rhVEGF165. Surfaces with nano-anchored ODN strands and nonconjugated VEGF have shown increased proliferation to 74,073 cells on average during the fi rst three days after which the number of cells decreased to a mean of 63,570 cells and slowly increased towards the end of the observation period to an average number of 83,353 cells. Only on the surface loaded with conjugated rhVEGF165 hybridised to complementary ODN strands HUVECS continued to proliferate to a number of 177,192 over the period of four weeks. Differences in cell numbers between this surface and the two latter ones were signifi cant at day 7 and day 28, respectively (p < 0.001, p < 0.001) (Fig. 2c) .
Induction of vWF in mesenchymal stem cells
Supernatants from discs with blank SAE surfaces had not shown any induction of vWF in the immunofl uorescent images at any interval (Fig. 3a-c) . Non-conjugated rhVEGF165 adsorbed to SAE surfaces without (Figs. 3d, e) and with nano-anchored ODN (Figs. 4a,b) and released into the supernatant clearly has shown to induce expression of vWF. The vWF was located perinuclear in the cytoplasm of the hMSCs. The same held true for the conjugated rhVEGF165 released from the discs with nano-anchored ODN. The vWF was clearly visible after exposure to supernatants also from the late intervals (Figs 4c,d ).
Discussion
The present study has shown that rhVEGF165 can be effectively immobilised on titanium surfaces through conjugation to oligonucleotides and hybridisation to complementary nucleotide strands anchored to the surface by anodic polarisation induced oxide growth. The amount of VEGF that was washed away from the surface after loading was the smallest in the group of SAE surfaces with H Schliephake et al. Angiogenesis on titanium surfaces ODN strands combined with conjugated VEGF indicating that binding of VEGF to the titanium surface through this modular system is the most effective. This supports previous reports showing that binding of organic molecules to titanium surfaces through hybridisation of ODN strands is specifi c and that other growth factors like rhBMP2 can be effectively immobilised on the surface using this system (Schliephake et al., 2012) . The portion of growth factor that has been retained is lower than what has been reported for carboxymethylchitosan (94 %) and hydroxylapatite coatings (85 %) (Hu et al., 2010) , but it was considerably higher than that reported for polydopamine grafting (52 %, Poh et al., 2010) or coatings with collagen and heparin (38-42 % (Wulf-Brandstetter et al., 2006) . The second best group in terms of growth factor retention have been the SAE surfaces with ODN strands combined with non-conjugated VEGF whereas the non-conjugated VEGF adsorbed to the blank SAE titanium surface had shown the lowest degree of growth factor retention on the surface. This has been different for rhBMP2, where titanium surfaces with ODN strands had bound the non-conjugated growth factor to an even smaller extend than blank SAE titanium surfaces (Schliephake et al., 2012) . The different behaviour of the two nonconjugated growth factors under these conditions may be explained by differences in both structure and size of the two different growth factors, which may account for non-specifi c interaction between the ODN strands and the growth factor molecules. However, despite the higher potential of immobilisation for conjugated rhVEGF165 bound to ODN strands, the release characteristic for this specifi cally bound VEGF has been very similar to non-conjugated VEGF particularly during early periods of release and is in contrast to the previously reported results for BMP2 (Schliephake et al., 2012) . The burst release of much higher amounts of non-conjugated growth factor in the present study compared to BMP may be explained by the increased amount of conjugated VEGF, which has been used for immobilisation on the titanium surface, indicating that the amount of growth factor that can be immobilised on the titanium surface though hybridisation on ODN strands is limited and excess growth factor such as higher amounts of VEGF in the present study will be rapidly released. The reason for this limitation may be that the process of hybridisation between the ODN strands immobilised on the titanium surface and those conjugated to the growth factor is impeded by the size of the growth factor molecule. The portion of conjugated growth factor that would be left on the surface without specifi c binding would then be released in the burst like fashion that has been observed in the present study. A possible solution for this problem could be the use of smaller peptide fragments that carry the receptor binding domain.
In contrast to a similar release of absolute amounts of growth factor during the fi rst week, calculations of the cumulative fi gures have shown that the percentage of growth factor released during this period is only 54.0 % in the group of specifi cally bound VEGF, whereas signifi cantly greater portions between 78.9 and 97.4 % of the non-conjugated VEGF have been released from the titanium surfaces with and without ODN strands. Because the absolute amounts of VEGF released in the following 3 weeks is very similar in all three groups but almost 50 % of the conjugated rhVEGF165 have remained immobilised on the surfaces in the group with specifi cally bound growth factor this may indicate that the large portion of immobilised growth factor in this group has accounted for the signifi cant increase in proliferation of HUVECs on these surfaces compared to those with adsorbed nonconjugated growth factor. The question may arise, whether surface topography would have an effect on the results of HUVEC proliferation. A comparison with smooth machined or polished titanium surfaces would have quite likely resulted in a difference in terms of attachment and proliferation of HUVECs. However, the current standard of surface characteristics of oral implants are microrough sandblasted and/or acid etched surfaces. Moreover, previous studies have shown that the use of biological signals is more challenging in microrough surfaces than on smooth Ti surfaces with respect to in vivo effects (Schliephake et al., 2005; Schliephake et al., 2009) . Thus, developments aiming for clinical applications would preferably focus on this type of surfaces.
The released amounts of VEGF itself have shown to be angiogenic also for the conjugated VEGF as could be seen from the induction of vWF in mesenchymal stem cells, where no difference has been found between the conjugated and the non-conjugated VEGF with respect to staining intensity. This indicates that the ODN complementary strand that had been conjugated to the VEGF molecule has obviously not reduced the ability of the growth factor to bind to its receptor and activate the expression of vWF. The induction of vWF in mesenchymal stem cells during differentiation into endothelial phenotype has been shown previously by Oswald et al. (2004) .
The percentage of release of conjugated VEGF from the different surfaces has shown an interesting similarity of the release curves of VEGF from calcium phosphate ceramics with a high release kinetic for adsorbed VEGF with release of approx. 85 % and a low release of co-precipitated VEGF of approx. 45 % within the fi rst 7 to 10 days of release (Wernike et al., 2010) . In vivo the low release characteristic has shown increased vessel formation and biomaterial incorporation after implantation into cranial bone. Although the in vivo behaviour of the functionalised titanium surfaces in the present in vitro study is diffi cult to predict, the release characteristic provided by the ODN mediated immobilisation appears to be favourable with respect to bone tissue response.
Conclusions
The present study has shown that VEGF molecules can be effectively immobilised by conjugation to ODN strands and hybridisation to complementary ODN strands that have been anchored to titanium surfaces. The released VEGF molecules have exhibited angiogenic activity by induction of VWF and in conjunction with the molecules immobilised to the surface have signifi cantly enhanced proliferation of human umbilical venous endothelial cells.
